| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | PKC ACTIVATORS AND ANTICOAGULANT IN REGIMEN FOR TREATING STROKE | US13178843 | 2011-07-08 | US20120034205A1 | 2012-02-09 | Daniel L. Alkon |
| The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke. | ||||||
| 82 | DAG-TYPE AND INDIRECT PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE | US13178821 | 2011-07-08 | US20120020948A1 | 2012-01-26 | Daniel L. Alkon |
| The present disclosure provides a method for treating stroke by administering an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator, wherein the PKC activator may be administered before, after, or at the same time as the rTPA. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are compositions and kits comprising rTPA and a PKC activator for treating stroke. | ||||||
| 83 | Non-neurotoxic plasminogen activating factors for treating stroke | US12163828 | 2008-06-27 | US08071091B2 | 2011-12-06 | Robert Medcalf; Mariola Söhngen; Wolfgang Söhngen; Wolf-Dieter Schleuning |
| The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to provide a new therapeutic concept for treating stroke in humans. | ||||||
| 84 | Glycopegylation methods and proteins/peptides produced by the methods | US12496595 | 2009-07-01 | US08063015B2 | 2011-11-22 | Shawn DeFrees; David A. Zopf; Robert J. Bayer; David James Hakes; Caryn L. Bowe; Xi Chen |
| The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | ||||||
| 85 | PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS | US12822071 | 2010-06-23 | US20100330083A1 | 2010-12-30 | Charles P. SEMBA |
| A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, as well as in kits. In a preferred embodiment, peripheral thrombosis is treated in a mammal comprising delivering to the mammal via a catheter an effective amount of this solution. | ||||||
| 86 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | US12496595 | 2009-07-01 | US20100048456A1 | 2010-02-25 | Shawn DeFrees; David A. Zopf; Robert J. Bayer; David James Hakes; Caryn Bowe; Xi Chen |
| The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | ||||||
| 87 | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers | US10021508 | 2001-10-22 | US20020091229A1 | 2002-07-11 | Jeffrey A. Hubbell; Chandrashekhar P. Pathak; Amarpreet S. Sawhney; Neil P. Desai; Jennifer L. Hill |
| Hydrogels of polymerized and crosslinked macromers comprising hydrophilic oligomers having biodegradable monomeric or oligomeric extensions, which biodegradable extensions are terminated on free ends with end cap monomers or oligomers capable of polymerization and cross linking are described. The hydrophilic core itself may be degradable, thus combining the core and extension functions. Macromers are polymerized using free radical initiators under the influence of long wavelength ultraviolet light, visible light excitation or thermal energy. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. Preferred applications for the hydrogels include prevention of adhesion formation after surgical procedures, controlled release of drugs and other bioactive species, temporary protection or separation of tissue surfaces, adhering of sealing tissues together, and preventing the attachment of cells to tissue surfaces. | ||||||
| 88 | Pharmaceutical preparation containing protein C and a thrombolytically active substance | US07899866 | 1992-06-17 | US06403556B1 | 2002-06-11 | Johann Eibl; Anton Philapitsch; Hans Peter Schwarz |
| A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy. | ||||||
| 89 | Pharmaceutical preparation containing protein C and a thrombolytically active substance | US456684 | 1995-06-01 | US5830467A | 1998-11-03 | Johann Eibl; Anton Philapitsch; Hans Peter Schwarz |
| A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy. | ||||||
| 90 | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers | US379848 | 1995-01-27 | US5626863A | 1997-05-06 | Jeffrey A. Hubbell; Chandrashekhar P. Pathak; Amarpreet S. Sawhney; Neil P. Desai; Jennifer L. Hill |
| Hydrogels of polymerized and crosslinked macromers comprising hydrophilic oligomers having biodegradable monomeric or oligomeric extensions, which biodegradable extensions are terminated on free ends with end cap monomers or oligomers capable of polymerization and cross linking are described. The hydrophilic core itself may be degradable, thus combining the core and extension functions. Macromers are polymerized using free radical initiators under the influence of long wavelength ultraviolet light, visible light excitation or thermal energy. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. Preferred applications for the hydrogels include prevention of adhesion formation after surgical procedures, controlled release of drugs and other bioactive species, temporary protection or separation of tissue surfaces, adhering of sealing tissues together, and preventing the attachment of cells to tissue surfaces. | ||||||
| 91 | Methods for thrombolytic therapy | US503028 | 1990-04-02 | US5185149A | 1993-02-09 | John J. Baldwin; Paul A. Friedman; Andrew M. Stern |
| Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator. | ||||||
| 92 | Protein absorption enhancing agents | US19564 | 1987-02-27 | US5002930A | 1991-03-26 | Stanley J. Sarnoff; Burton E. Sobel |
| The absorption rate of proteins with medicinal properties in the blood is enhanced by administering the protein intramuscularly together with an absorption enhancing agent, e.g. hydroxylamine or a salt thereof. | ||||||
| 93 | Injection method and apparatus with electrical blood absorbing stimulation | US735311 | 1985-05-20 | US4832682A | 1989-05-23 | Stanley J. Sarnoff |
| A method of treating a patient with liquid medicament under circumstances where intravenous injection is not practical but the fast response time of an intravenous injection is desirable, including the treatment of individuals undergoing heart attack symptoms with t-PA. The method comprises the steps of injecting the liquid medicament t-PA preferably with a blood absorption enhancing agent such as hydroxylamine hydrochloride into the muscle tissue of the patient, applying to the patient which has received the injection repeated blood flow stimulating cycles, each of which includes a period of electrical stimulus during which the muscle tissue which has received the injection tenses followed by a period of no electrical stimulus during which the muscle tissue which received the injection is allowed to relax inducing enhanced blood flow within the muscle tissue, and continuing the application of the repeated blood flow stimulating cycles until the injected liquid medicament has been sufficiently absorbed into the enhanced blood flow to achieve a desired possible patient response of reperfusion and apparatus for carrying out the method. | ||||||
| 94 | Gene vaccine for preventing and treating severe fever with thrombocytopenia syndrome | US16161189 | 2018-10-16 | US20190231862A1 | 2019-08-01 | Hyun-Tak Jin; Yong Bok Seo; Ju-A Shin |
| Provided is a gene vaccine composition for preventing and treating severe fever with thrombocytopenia syndrome (SFTS), including, as an active ingredient, at least one expression vector including a first polynucleotide encoding a glycoproteinN (Gn) derived from SFTS virus, a second polynucleotide encoding a glycoprotein C (Gc), a third polynucleotide encoding a nucleocapsid protein (NP) derived from the SFTS virus, and a fourth polynucleotide encoding a nonstructural protein (NS) derived from the SFTS virus. | ||||||
| 95 | HETEROMULTIVALENT PARTICLE COMPOSITIONS | US15832526 | 2017-12-05 | US20180318443A1 | 2018-11-08 | Anirban Sen Gupta; Madhumitha Ravikumar; Christa Modery |
| A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety. | ||||||
| 96 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE THROMBOLYSIS | US15523900 | 2015-11-03 | US20180311322A1 | 2018-11-01 | Victor Gurewich |
| Provided herein are methods, compositions, and kits for safe and effective thrombolysis, e.g., in therapy for a potential stroke or acute myocardial infarction (“AMI”). | ||||||
| 97 | Therapeutic magnetic control systems and contrast agents | US15155386 | 2016-05-16 | US10029008B2 | 2018-07-24 | Francis M. Creighton |
| A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. Examples of vascular occlusions targeted by the system include, but are not limited to, atherosclerotic plaques, including fibrous caps, fatty buildup, coronary occlusions, arterial stenosis, restenosis, vein thrombi, arterial thrombi, cerebral thrombi, embolisms, hemorrhages, other blood clots, and very small vessels. | ||||||
| 98 | Diagnostic marker for treatment of cerebral ischemia | US14657777 | 2015-03-13 | US09913899B2 | 2018-03-13 | Lawrence M. Kauvar; Damir Janigro |
| Identification of candidates for treatment and treatment of subjects experiencing cerebral ischemia wherein the treatment employs a thrombolytic or thrombectomy agent and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are determined by testing the blood of a patient for total S-100B or for S-100BB as a marker of blood brain barrier integrity. | ||||||
| 99 | PKC activators and anticoagulant in regimen for treating stroke | US14818576 | 2015-08-05 | US09889183B2 | 2018-02-13 | Daniel L. Alkon |
| The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke. | ||||||
| 100 | Gelatinase inhibitors and prodrugs | US15139055 | 2016-04-26 | US09867805B2 | 2018-01-16 | Mayland Chang; Shahriar Mobashery; Mijoon Lee |
| The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | ||||||
QQ群二维码
意见反馈
意见反馈